USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Nektar Therapeutics (NASDAQ:NKTR) saw its stock soar 140% following promising Phase 2b trial results for its experimental treatment rezpegaldesleukin in moderate-to-severe atopic dermatitis. The ...

US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced statistically significant data from the 16-week ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study ...

The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...